Erste Asset Management GmbH Sells 240,000 Shares of Guardant Health, Inc. (NASDAQ:GH)

Erste Asset Management GmbH reduced its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 25.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 692,600 shares of the company’s stock after selling 240,000 shares during the period. Erste Asset Management GmbH owned about 0.56% of Guardant Health worth $21,144,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swiss National Bank boosted its holdings in Guardant Health by 1.0% in the fourth quarter. Swiss National Bank now owns 241,900 shares of the company’s stock valued at $7,390,000 after acquiring an additional 2,500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Guardant Health by 5.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,488 shares of the company’s stock valued at $931,000 after acquiring an additional 1,502 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Guardant Health in the fourth quarter valued at approximately $2,211,000. Arizona State Retirement System boosted its holdings in Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock valued at $1,089,000 after acquiring an additional 403 shares during the last quarter. Finally, Aigen Investment Management LP boosted its holdings in Guardant Health by 35.9% in the fourth quarter. Aigen Investment Management LP now owns 25,957 shares of the company’s stock valued at $793,000 after acquiring an additional 6,854 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $43.10 on Thursday. The company has a market capitalization of $5.32 billion, a PE ratio of -12.11 and a beta of 1.50. The business has a fifty day moving average price of $42.40 and a two-hundred day moving average price of $32.61. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. The Goldman Sachs Group boosted their price target on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Piper Sandler boosted their price target on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Canaccord Genuity Group upped their target price on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Barclays assumed coverage on Guardant Health in a research report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. Finally, Raymond James reaffirmed an “outperform” rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has an average rating of “Buy” and an average target price of $48.40.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 2,668 shares of company stock worth $95,208 in the last quarter. 5.50% of the stock is currently owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.